Global Analgesics Market Report to 2026 – Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market –

Global Analgesics Market Report to 2026 – Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market –

Global Analgesics Market Report to 2026 – Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market –

DUBLIN–(BUSINESS WIRE)–The “Analgesics – Global Market Trajectory & Analytics” report has been added to’s offering.

Amid the COVID-19 crisis, the global market for Analgesics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period.

Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.

The U.S. Market is Estimated at $15.2 Billion in 2021, While China is Forecast to Reach $8.2 Billion by 2026

The Analgesics market in the U.S. is estimated at US$15.2 Billion in the year 2021. The country currently accounts for a 32.76% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.

Opioids Segment to Reach $18.4 Billion by 2026

Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$14.9 Billion in 2020, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales in 2020. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026.

Select Competitors (Total 146 Featured) –

  • Amneal Pharmaceuticals Inc
  • Apotex Inc
  • AstraZeneca Plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Iroko Pharmaceuticals, LLC
  • Johnson & Johnson
  • Lupin Limited
  • Novartis AG
  • Reckitt Benckiser Group plc
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

Key Topics Covered:




  • Analgesics – Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • A Prelude to Analgesics
  • Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain
  • Key Segments
  • Opioid Analgesics
  • Non-Opioid Analgesics
  • NSAIDs
  • Topical NSAIDs
  • Others
  • Acetaminophen
  • Adjuvant Analgesics
  • Impact of COVID-19 on Analgesics
  • NSAIDs
  • NSAIDs Tend to Decrease Effectiveness of COVID-19 Vaccines, States a Yale University Study
  • Opioid
  • Acetaminophen
  • Global Analgesics Market to Witness Rapid Growth
  • Drugs Indicated for Pain Management
  • The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth
  • Non-Opioids: Fastest Growing Category
  • Competition
  • Recent Market Activity



  • Growing Aging Population & Increasing Burden of Chronic Diseases Spurs
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • Advancements in Design and Delivery of Analgesic Drugs
  • Development of Safer Opioids with More Safer Profiles
  • Drug Pipeline with Efficacious Drugs
  • OTC Analgesics Market to Witness Fastest Growth
  • Topical Analgesics Market Holds Significant Share
  • Combination Therapies Gain Prominence
  • A Few Novel Analgesic Products under Development
  • E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period
  • Neuropathic Pain Management: Market with High Potential
  • Migraine Market: A Core Vertical in CNS Pain Management
  • Migraine Care: Select Patent Expiries (2013-2015)
  • Reyvow, Eli Lilly’s Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
  • Three New Migraine Drugs Obtain FDA Approval
  • Eli Lilly’s Emgality Receives FDA Approval
  • Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market




For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900